GLP-1R Agonist Salt Synthesis for Stable Crystalline Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological interventions for Type 2 diabetes mellitus (T2DM) and associated cardiometabolic diseases, such as obesity, have limited efficacy and are associated with significant side effects, and there is a need for more effective and conveniently administered treatments that address declining beta-cell function and obesity.
Innovation Solution
Development of a GLP-1R agonist, 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, in the form of a pharmaceutically acceptable salt, such as its 1,3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt, utilizing specific synthetic processes to produce stable crystalline forms that enhance solubility, stability, and ease of formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmacological interventions for T2DM are used, then glycemic control is achieved, but side effects and limited efficacy occur
Solution Approach 1:
The patent employs parameter changes by developing a novel GLP-1R agonist compound with specific molecular structure modifications (introduction of fluorobenzyl group, oxetan-2-ylmethyl substitution) to improve efficacy while reducing side effects compared to conventional T2DM medications
Solution Approach 2:
The invention creates a composite pharmaceutical formulation by combining the GLP-1R agonist with specific salts (1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine) to enhance solubility, stability, and bioavailability, thereby improving therapeutic efficacy while minimizing adverse effects
2Reliability
If GLP-1R agonist is developed as a new compound, then efficacy and side effect profile are improved, but manufacturing complexity increases
Solution Approach 1:
The synthesis pathway is segmented into distinct modular steps: (a) formation of the core pyridine-piperidine linkage, (b) introduction of the fluorobenzyl ether group, (c) benzimidazole ring formation, and (d) salt formation. This segmentation allows each step to be optimized independently, managing manufacturing complexity while achieving the desired efficacy
Solution Approach 2:
The patent uses strategically designed intermediate compounds (such as the fluorobenzyl ether-substituted pyridine and the oxetan-2-ylmethyl-benzimidazole carboxylic acid) as building blocks that can be synthesized separately and then combined. This intermediary approach simplifies the overall manufacturing process by breaking down the complex molecule synthesis into manageable stages
Data Source
AI summary
The invention provides methods and certain intermediates for preparing 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid 1,3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt, and processes for preparing these intermediates.